K Hotta

Summary

Affiliation: Okayama University
Country: Japan

Publications

  1. ncbi New cytotoxic agents: a review of the literature
    Katsuyuki Hotta
    Health and Environmental Center, Okayama University, 2 1 1, Tsushimanaka, Okayama 700 8530, Japan
    Crit Rev Oncol Hematol 55:45-65. 2005
  2. ncbi Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    Cancer 109:939-48. 2007
  3. ncbi Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    J Cancer Res Clin Oncol 135:117-23. 2009
  4. ncbi Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Anticancer Res 25:2429-34. 2005
  5. ncbi Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Lung Cancer 62:236-41. 2008
  6. ncbi Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    K Hotta
    Department of Medicine II, Okayama University Medical School, Okayama
    Ann Oncol 16:1817-23. 2005
  7. ncbi An intensive group therapy programme for smoking cessation using nicotine patch and internet mailing supports in a university setting
    K Hotta
    Health and Medical Section, Health and Environmental Center, Okayama University, Tsushima Naka, Okayama, Japan
    Int J Clin Pract 61:1997-2001. 2007
  8. ncbi Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Acta Oncol 44:717-22. 2005
  9. ncbi Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students
    Katsuyuki Hotta
    Health and Environmental Center, Okayama University, Okayama, Japan
    PLoS ONE 2:e803. 2007
  10. ncbi Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama, Japan
    Cancer J 11:417-24. 2005

Collaborators

Detail Information

Publications76

  1. ncbi New cytotoxic agents: a review of the literature
    Katsuyuki Hotta
    Health and Environmental Center, Okayama University, 2 1 1, Tsushimanaka, Okayama 700 8530, Japan
    Crit Rev Oncol Hematol 55:45-65. 2005
    ..In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents...
  2. ncbi Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    Cancer 109:939-48. 2007
    ..The objective of the current investigation was to determine the time trends in outcomes for the patients in those trials...
  3. ncbi Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    J Cancer Res Clin Oncol 135:117-23. 2009
    ..Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma...
  4. ncbi Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Anticancer Res 25:2429-34. 2005
    ..Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum-tolerated dose (MTD), a phase I study in patients with advanced NSCLC was conducted...
  5. ncbi Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Lung Cancer 62:236-41. 2008
    ..However, this has been criticized because the better survival in such subpopulation might be attributable simply to their favorable natural history, rather than any treatment effect...
  6. ncbi Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    K Hotta
    Department of Medicine II, Okayama University Medical School, Okayama
    Ann Oncol 16:1817-23. 2005
    ....
  7. ncbi An intensive group therapy programme for smoking cessation using nicotine patch and internet mailing supports in a university setting
    K Hotta
    Health and Medical Section, Health and Environmental Center, Okayama University, Tsushima Naka, Okayama, Japan
    Int J Clin Pract 61:1997-2001. 2007
    ..We aimed to investigate the efficacy of intensive cessation programme delivered in a group format using nicotine patch therapy and internet mailing supports for our university employees...
  8. ncbi Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Acta Oncol 44:717-22. 2005
    ..57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients...
  9. ncbi Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students
    Katsuyuki Hotta
    Health and Environmental Center, Okayama University, Okayama, Japan
    PLoS ONE 2:e803. 2007
    ..The aim of this study was to compare the results from the QFT with those from the tuberculin skin test (TST) in a population deemed to be at a low risk for infection with Mycobacterium tuberculosis...
  10. ncbi Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama, Japan
    Cancer J 11:417-24. 2005
    ..The aim of this study was to retrospectively identify and evaluate these possible factors...
  11. ncbi Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Japan
    Curr Opin Oncol 18:144-50. 2006
    ..This review will focus on recent clinical trials for adjuvant chemotherapy, and will help to interpret the applicability of these results to daily clinical practice...
  12. ncbi Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama 700 8558, Japan
    Oncol Rep 17:313-7. 2007
    ..Our results indicate that senescence might be a major anti-tumor mechanism of gefitinib in these NSCLC cells regardless of the EGFR gene mutation status...
  13. ncbi Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:632-7. 2007
    ..The aim of this study was to clarify its association. We also examined whether this association could be affected by previous gefitinib treatment...
  14. ncbi Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama 700 8558, Japan
    Anticancer Res 27:1737-41. 2007
    ..In this report, we investigated its role using the data from 110 non-small cell lung cancer (NSCLC) patients...
  15. ncbi Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:402-7. 2007
    ..The association between the objective response to chemotherapy and survival has not yet been fully evaluated using large cohorts in advanced non-small cell lung cancer...
  16. ncbi Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 4:311-7. 2009
    ..We examined the association between differences in overall survival and time to progression (TTP) using a literature survey...
  17. ncbi Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
    K Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, Japan
    Ann Oncol 20:829-34. 2009
    ....
  18. ncbi A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer
    Katsuyuki Hotta
    Departmnet of Internal Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 45:77-84. 2004
    ....
  19. ncbi Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer
    K Hotta
    Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Thorac Cardiovasc Surg 51:283-7. 2003
    ..The aim of this study was to evaluate clinicopathologic characteristics, type of locoregional recurrence, pattern of subsequent failure, and survival after the recurrence...
  20. ncbi Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 5:179-84. 2010
    ..We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib...
  21. ncbi Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Kitaku, Okayama, 700 8558, Japan
    Expert Rev Anticancer Ther 11:991-7. 2011
    ..This article summarizes clinical study results in advanced non-small-cell lung cancer, so that we can comprehensively understand the toxicities expected with erlotinib in non-small-cell lung cancer patients...
  22. ncbi Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Kitaku, Okayama, Japan
    J Thorac Oncol 5:1668-72. 2010
    ..The impact of demographic and psychosocial characteristics on the decisional role of patients is also examined...
  23. ncbi Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Kitaku, Okayama 700 8558, Japan
    Lung Cancer 70:308-12. 2010
    ..The relationship between poor performance status (PS) and toxicity during chemotherapy is controversial. We examined this for erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients...
  24. ncbi Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    J Clin Oncol 22:3860-7. 2004
    ..This study was aimed at re-evaluating the effectiveness of adjuvant chemotherapy in patients with resected NSCLC, by performing a meta-analysis of relevant trials...
  25. ncbi Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    J Clin Oncol 22:3852-9. 2004
    ..We therefore did a meta-analysis of trials that compared cisplatin-based chemotherapy with carboplatin-based chemotherapy...
  26. ncbi An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 46:61-76. 2004
    ..The aim of the present study was to identify elderly-specific clinical trials for advanced non-small cell lung cancer (NSCLC) and to clarify the study design and patient characteristics entered of each of these trials...
  27. ncbi Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 46:255-61. 2004
    ..We have retrospectively analyzed the efficacy and tolerability of gefitinib in patients with advanced NSCLC treated at Okayama University Hospital...
  28. ncbi Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
    K Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Ann Oncol 15:1782-9. 2004
    ..The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone...
  29. ncbi Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    PLoS ONE 6:e26646. 2011
    ..A literature survey was conducted to examine whether survival post-progression (SPP) has improved over the years and to what degree SPP correlates with overall survival (OS)...
  30. ncbi A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705
    Hiroshige Yoshioka
    Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
    J Thorac Oncol 5:99-104. 2010
    ..The aim of this trial was to evaluate the efficacy and toxicity of erlotinib in Japanese patients with EGFR-wt tumors...
  31. ncbi A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503
    Yoshihiko Segawa
    Department of Respiratory Medicine, National Hospital Organization Yamaguchi Ube Medical Center, 685 Higashi Kiwa, Ube, Yamaguchi, Japan
    J Thorac Oncol 5:1430-4. 2010
    ..We conducted a randomized phase II study to evaluate the efficacy and safety of the combination of docetaxel and S-1 in the second-line setting...
  32. ncbi Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment
    Masaru Jida
    Departments of Cancer and Thoracic Surgery, Graduate School of Medicine, Okayama University, Kita ku, Okayama, Japan
    Cancer Sci 100:1931-4. 2009
    ..Thus, patients who have smoked less than 13 PY might be candidates for gefitinib treatment when EGFR mutation status cannot be determined...
  33. ncbi A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer
    Takuo Shibayama
    Department of Respiratory Medicine, NHO Minami Okayama Medical Center, 4066 Hayashima, Hayashima cho, Tsukubo Gun, Okayama 701 0304, Japan
    Lung Cancer 53:189-95. 2006
    ..9+/-3.6) was significantly higher than that in non-responders (10.9+/-0.4). This phase I study showed the safety and activity of two-drug combination of amrubicin and topotecan in patients with relapsed or ED-SCLC...
  34. ncbi A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer
    K Hotta
    Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 31:596-600. 2001
    ..The combination of cisplatin and vinorelbine repeated every 3 weeks is well tolerated and has shown promising anti-tumor activity against non-small cell lung cancer...
  35. ncbi Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer
    Shinobu Hosokawa
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 66:107-13. 2009
    ..Moreover, the impact of downstream signaling of EGFR on clinical features in patients with non-small cell lung cancer (NSCLC) remains undetermined...
  36. ncbi Isolated metastasis of lung cancer to the thyroid gland
    Masahiro Osawa
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 58:156-8. 2007
    ..This is the first report to document an isolated recurrence of the lung cancer to the thyroid...
  37. ncbi Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer
    Hirokazu Watanabe
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 33:626-30. 2003
    ..CONCLUSIONS: The combination of paclitaxel 210 mg/m(2) and cisplatin 80 mg/m(2) was found to be a well-tolerated active regimen in Japanese patients with advanced non-small cell lung cancer...
  38. ncbi ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
    Tetsuya Fujii
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 59:377-84. 2008
    ..Further study is needed to clarify the value of molecular predictors for customizing therapy for patients with NSCLC...
  39. ncbi Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 52:99-103. 2006
    ..However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation...
  40. ncbi Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results
    Isao Oze
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    PLoS ONE 4:e7835. 2009
    ..The objective of the current investigation was to determine the time trends in outcomes for the patients in those trials...
  41. ncbi Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment
    Y Fujiwara
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    Ann Oncol 22:376-82. 2011
    ..However, few studies have formally assessed possible changes in the TRD rate over the past two decades...
  42. ncbi Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer
    Junichi Soh
    Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Int J Cancer 121:1162-7. 2007
    ....
  43. ncbi Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Hiroshi Suehisa
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama, Japan
    J Clin Oncol 25:3952-7. 2007
    ..The present study evaluated whether the EGFR status could be used as a biologic predictor of the outcome of adjuvant chemotherapy with uracil-tegafur...
  44. ncbi Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer
    Hitoshi Kusaba
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 32:43-7. 2002
    ..We determined 1250 mg/m(2) of gemcitabine combined with 80 mg/m(2 )of cisplatin to be the recommended dose...
  45. ncbi The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
    Shuji Ichihara
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Int J Cancer 120:1239-47. 2007
    ..Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive EGFR mutation...
  46. ncbi Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007
    Yoshihiko Segawa
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital, Kitaku, Okayama, Japan
    J Clin Oncol 28:3299-306. 2010
    ..To demonstrate the efficacy of docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (LA-NSCLC)...
  47. ncbi Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
    Keiichi Fujiwara
    Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    Anticancer Res 25:547-9. 2005
    ..Gefitinib might restore chemosensitivity to previously chemorefractory patients...
  48. ncbi Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer
    Shoichi Kuyama
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
    J Thorac Oncol 3:477-82. 2008
    ..The aim of this study was to evaluate their relationships...
  49. ncbi Construction of pRES18 and pRES19, Streptomyces-Escherichia coli shuttle vectors carrying multiple cloning sites
    J Ishikawa
    Department of Bioactive Molecules, National Institute of Health, Tokyo, Japan
    FEMS Microbiol Lett 145:113-6. 1996
    ..coli (beta-lactamase (bla) and beta-galactosidase (lacZ). These shuttle vectors are capable of carrying DNA fragments as long as 10 kb, of being maintained in S. griseus, S. lavendulae and S. lividans, and are compatible with pIJ702...
  50. ncbi Cloning of a canine gene homologous to the human interleukin-8-encoding gene
    J Ishikawa
    Department of Bioactive Molecules, National Institute of Health, Shinjuku, Tokyo, Japan
    Gene 131:305-6. 1993
    ..Thus, it seems very likely that the cloned gene is a canine homologue of hIL8...
  51. ncbi A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer
    Keiichi Fujiwara
    Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, 1711 1 Tamasu, Okayama 701 1192, Japan
    Cancer Chemother Pharmacol 57:755-60. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC)...
  52. ncbi Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Cancer Sci 99:303-8. 2008
    ....
  53. ncbi Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Medical Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 59:81-7. 2008
    ..The aim of this study was to investigate the prognostic value of the serum KL-6 levels in advanced NSCLC patients treated with gefitinib and thus determine its association with the EGFR mutation status...
  54. ncbi Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer
    Shigeki Umemura
    Department of Hematology, Oncology and Respiratory Medicine Okayama University Graduate School of Medicine and Dentistry, Japan
    Intern Med 44:979-82. 2005
    ..Then, he was considered to have developed systemic tumor emboli, a rare complication. The clinical presentation of this patient was difficult to discriminate from that of ILD, and TBLB was useful in the differential diagnosis...
  55. ncbi Recent improvement in lung cancer screening: a comparison of the results carried out in two different time periods
    Takuji Kitajima
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
    Acta Med Okayama 60:173-9. 2006
    ....
  56. ncbi Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer
    Shigeki Umemura
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    J Cancer Res Clin Oncol 133:519-24. 2007
    ..The purpose of this study is to elucidate the influence of serum arginine-vasopressin (AVP) level on prognosis of extensive-disease small-cell lung cancer (ED-SCLC)...
  57. ncbi Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells
    Nagio Takigawa
    Department of Respiratory Medicine, Okayama University Hospital, Okayama 700 8558, Japan
    Oncol Rep 17:983-7. 2007
    ..Irinotecan with gefitinib or imatinib might be effective for SCLC refractory to irinotecan...
  58. ncbi A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
    Masahiro Tabata
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Cancer Chemother Pharmacol 60:1-6. 2007
    ....
  59. ncbi Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial
    Katsuyuki Kiura
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:44-50. 2007
    ..To determine the recommended dose and evaluate the response rate and toxicity of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for non-small cell lung cancer (NSCLC) patients with stage IIIB or IV...
  60. ncbi Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Lung Cancer 55:343-8. 2007
    ..The aim of this study was to identify risk factors for hepatic dysfunction during cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer (NSCLC)...
  61. ncbi The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells
    Nagio Takigawa
    Department of Respiratory Medicine, Okayama University Hospital, Okayama 700 8558, Japan
    Oncol Rep 15:837-42. 2006
    ..These findings suggest that amrubicin alone and in combination with cisplatin or irinotecan is effective against SCLC refractory to irinotecan and/or cisplatin...
  62. ncbi Coding region structure of interleukin-8 gene of human lung giant cell carcinoma LU65C cells that produce LUCT/interleukin-8: homogeneity in interleukin-8 genes
    K Hotta
    Department of Antibiotics, National Institute of Health, Tokyo, Japan
    Immunol Lett 24:165-9. 1990
    ..Thus, it seems likely that human cells possess IL-8 genes with the homogeneous coding region so that they may first produce the same mature protein with N-terminal AVLPR (= LUCT) which was then truncated...
  63. ncbi Successful treatment of limited disease-small cell lung cancer with multimodality treatment consisting of concurrent chemoradiotherapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation and surgical resection
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama
    Intern Med 42:1223-7. 2003
    ..He has been alive without recurrence for seven years. This multimodality treatment appeared to be effective for this patient. However, further investigation is necessary to clarify the role of multimodality treatment...
  64. ncbi FramePlot: a new implementation of the frame analysis for predicting protein-coding regions in bacterial DNA with a high G + C content
    J Ishikawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo, Japan
    FEMS Microbiol Lett 174:251-3. 1999
    ..These sequences can then be compared to the NCBI sequence database over the Internet. The program is freely available for academic purposes at http://www.nih.go.jp/jun/cgi-bin/frameplot.pl...
  65. ncbi Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Anticancer Drugs 19:431-3. 2008
    ..These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status...
  66. ncbi Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer
    Keiichi Fujiwara
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    Clin Cancer Res 11:1219-25. 2005
    ..3% of them. CONCLUSIONS: These results suggest that identification of promoter methylation of tumor suppressor genes in serum DNA could be useful for early detection of lung cancer...
  67. ncbi Induction chemotherapy, surgical resection, and high-dose chemotherapy for mediastinal nonseminomatous germ-cell tumor
    Hiroshi Date
    Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    J Thorac Cardiovasc Surg 130:1205-6. 2005
  68. ncbi [Large cell neuroendocrine carcinoma of the mediastinum]
    Daisuke Nojima
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
    Nihon Kokyuki Gakkai Zasshi 48:506-10. 2010
    ..The brain tumor demonstrated LCNEC. He received systemic chemotherapy of cisplatin and irinotecan, because his leg weakness and waddling gait had improved markedly after surgery followed by whole brain irradiation...
  69. ncbi Prophylactic cranial irradiation in small-cell lung cancer
    Yoshiro Fujiwara
    N Engl J Med 357:1977-8; author reply 1978. 2007
  70. ncbi Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer
    Yoshihiko Segawa
    Department of Medicine and Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
    Cancer 107:1866-72. 2006
    ..The current study assessed clinicopathologic factors affecting acquired resistance to gefitinib in previously treated patients with advanced NSCLC...
  71. ncbi Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients
    Hirokazu Watanabe
    Department of Radiology, Kobe University Graduate School of Medicine, 7 5 2 Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    Cancer Sci 97:214-8. 2006
    ..61-0.65). The introduction of MLS to UD could also improve intercriteria reproducibility between WHO and RECIST. It is important to apply the MLS when using RECIST for the comparable interobserver reproducibility attained with WHO...
  72. ncbi Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer
    Katsuyuki Hotta
    J Thorac Oncol 2:96. 2007
  73. ncbi Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study
    Katsuyuki Hotta
    Lung Cancer 50:413-5. 2005
  74. ncbi Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution
    Keitaro Matsuo
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    Am J Hematol 81:349-54. 2006
    ..Although we cannot exclude an effect of past exposure of other cytotoxic agents and radiotherapy as a cause of APL, APL inducibility of gefitinib should be clarified in the further study...
  75. ncbi Toxicity data in addition to survival data are important in evaluating the applicability of a chemotherapy regimen of advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Lung Cancer 49:277. 2005
  76. ncbi They also serve who only stand and wait: do individual clinical researchers, too? Hoping for individual patient data as public domain
    Keitaro Matsuo
    J Clin Oncol 23:1334-5. 2005